Clinical Trials

Phase 2 Active not recruiting

Carcinoma, Renal Cell

NCT02568267 2026-05-27

STARTRK-2

534 enrolled 1 FDA

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT04720157 2026-05-27

PSMAddition

1,140 enrolled

Prostatic Neoplasms

NCT05176483 2026-05-27

STELLAR-002

GastrointestinalGenitourinaryHead & NeckThoracic

1,314 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT05562830 2026-05-27

MK-3475-04A

48 enrolled

Carcinoma, Transitional Cell

NCT05710848 2026-05-27

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

75 enrolled

Phase 2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05849298 2026-05-27

PSMACare

49 enrolled

Prostatic Neoplasms

NCT05939414 2026-05-27

PSMA-DC

450 enrolled

Oligometastatic Prostate Cancer (OMPC)

NCT06120491 2026-05-27

EvoPAR-PR01

1,889 enrolled

Prostatic Neoplasms

NCT06136650 2026-05-27

MK-5684-004

1,314 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT06225596 2026-05-27

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

375 enrolled

Urinary Bladder Neoplasms

NCT06520345 2026-05-27

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

520 enrolled

Prostatic Neoplasms

NCT06780670 2026-05-27

PSMAcTION

Phase 2/3 Recruiting

443 enrolled

Prostatic Neoplasms

NCT07288359 2026-05-27

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

205 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms

NCT05943106 2026-05-26

PATAPSCO

100 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06147037 2026-05-26

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

GastrointestinalGenitourinaryHead & NeckThoracic

70 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Stomach Neoplasms, Colorectal Neoplasms

NCT06353386 2026-05-26

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06492122 2026-05-26

ProTACT

50 enrolled

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06533059 2026-05-26

A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors

110 enrolled

BreastGenitourinaryGynecologic

Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07049926 2026-05-26

MK-3475-03C

140 enrolled

Carcinoma, Renal Cell

NCT07293351 2026-05-26

A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

254 enrolled

Carcinoma, Renal Cell

NCT07405164 2026-05-26

MK-6482-043

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT07489495 2026-05-26

LITESPARK-034

758 enrolled

Carcinoma, Renal Cell

NCT02106572 2026-05-22

TIM

Phase 3 Terminated

174 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT03260894 2026-05-22

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

Phase 3 Completed

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04846920 2026-05-22

MK-6482-018

Phase 1 Completed

29 enrolled

Carcinoma, Renal Cell

NCT05043090 2026-05-22

SAMETA

148 enrolled

Phase 1 Active not recruiting

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT05277051 2026-05-22

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

152 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT05287945 2026-05-22

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

75 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Kidney Failure, Chronic, Kidney Neoplasms, Neoplasm Metastasis

NCT05682443 2026-05-22

PRESERVE-006

148 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

154 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms, Castration-Resistant

NCT06238479 2026-05-22

EXCEED

490 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06465069 2026-05-22

NEXUS-01

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

420 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06510374 2026-05-22

ABLE-32

454 enrolled

Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06545955 2026-05-22

ABLE-22

250 enrolled

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

NCT06842498 2026-05-22

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2 Recruiting

75 enrolled

Prostatic Neoplasms

NCT06925737 2026-05-22

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07028853 2026-05-22

MEVPRO-3

1,000 enrolled

Prostatic Neoplasms

NCT07114601 2026-05-22

OMNIRAY

BreastGastrointestinalGenitourinaryGynecologic

421 enrolled

Breast Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT07213674 2026-05-22

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

750 enrolled

Prostatic Neoplasms

NCT07218380 2026-05-22

FORAGER-2

450 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07227415 2026-05-22

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

224 enrolled

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT07419295 2026-05-22

TroFuse-031

590 enrolled

Urinary Bladder Neoplasms

NCT07529717 2026-05-22

CRIUS-1

42 enrolled

Prostatic Neoplasms

NCT06629779 2026-05-20

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06966024 2026-05-20

Study of DCC-2812 in Participants With Advanced Genitourinary Cancers

60 enrolled

Carcinoma, Renal Cell, Carcinoma, Transitional Cell

NCT06995677 2026-05-20

SURF302

Phase 2 Recruiting

90 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07334119 2026-05-20

Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

60 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Ovarian Epithelial, Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT07493512 2026-05-20

Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer

40 enrolled